Guillaume Eberst

448 total citations
18 papers, 201 citations indexed

About

Guillaume Eberst is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Guillaume Eberst has authored 18 papers receiving a total of 201 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 4 papers in Immunology. Recurrent topics in Guillaume Eberst's work include Cancer Immunotherapy and Biomarkers (7 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers) and Respiratory Support and Mechanisms (3 papers). Guillaume Eberst is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers) and Respiratory Support and Mechanisms (3 papers). Guillaume Eberst collaborates with scholars based in France, Australia and United Kingdom. Guillaume Eberst's co-authors include Virginie Westeel, Caroline Laheurte, Elizabeth Fabre, Olivier Adotévi, Françoise Le Pimpec‐Barthes, Déwi Vernerey, Laura Boullerot, Marion Jacquin, P. Jacoulet and Béatrice Gaugler and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Cochrane Database of Systematic Reviews.

In The Last Decade

Guillaume Eberst

15 papers receiving 195 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guillaume Eberst France 7 99 76 74 46 27 18 201
S. Collot France 7 83 0.8× 16 0.2× 81 1.1× 17 0.4× 8 0.3× 18 154
Xiaokai Feng China 7 29 0.3× 11 0.1× 32 0.4× 36 0.8× 9 0.3× 23 214
Changxing Ou China 7 17 0.2× 13 0.2× 38 0.5× 32 0.7× 4 0.1× 13 140
Thomas A Kite United Kingdom 7 33 0.3× 31 0.4× 19 0.3× 29 0.6× 5 0.2× 14 194
Alexandra M. Adams United States 8 83 0.8× 48 0.6× 21 0.3× 4 0.1× 20 0.7× 25 170
Lan Le United States 9 89 0.9× 47 0.6× 78 1.1× 3 0.1× 11 0.4× 17 238
Paola Vignali Italy 10 31 0.3× 19 0.3× 9 0.1× 46 1.0× 5 0.2× 19 281
Yoshimasa Otani Japan 9 183 1.8× 17 0.2× 64 0.9× 47 1.0× 5 0.2× 16 291
Donatella Casartelli Italy 5 23 0.2× 36 0.5× 36 0.5× 18 0.4× 6 126
Anabella Lucca Bianchi United States 7 53 0.5× 8 0.1× 60 0.8× 7 0.2× 3 0.1× 11 257

Countries citing papers authored by Guillaume Eberst

Since Specialization
Citations

This map shows the geographic impact of Guillaume Eberst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guillaume Eberst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guillaume Eberst more than expected).

Fields of papers citing papers by Guillaume Eberst

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guillaume Eberst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guillaume Eberst. The network helps show where Guillaume Eberst may publish in the future.

Co-authorship network of co-authors of Guillaume Eberst

This figure shows the co-authorship network connecting the top 25 collaborators of Guillaume Eberst. A scholar is included among the top collaborators of Guillaume Eberst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guillaume Eberst. Guillaume Eberst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Sultana, Habiba, Theo Vos, Reem Malouf, et al.. (2025). Prognostic value of blood eosinophils for predicting survival and treatment outcomes in people with non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2025(2). CD015783–CD015783. 1 indexed citations
2.
Eberst, Guillaume, et al.. (2024). Immune checkpoint inhibitor therapy associated with IgA nephropathy: a case report and literature review. Frontiers in Immunology. 15. 1393901–1393901. 2 indexed citations
3.
Eberst, Guillaume, et al.. (2023). Apports de l’exploration fonctionnelle à l'exercice et de la réhabilitation respiratoire dans le COVID long. Revue des Maladies Respiratoires. 40(7). 604–622. 1 indexed citations
4.
Laurent, Lucie, et al.. (2023). Evaluation of long-term sequelae by cardiopulmonary exercise testing 12 months after hospitalization for severe COVID-19. BMC Pulmonary Medicine. 23(1). 13–13. 11 indexed citations
5.
Guillien, Alicia, Marc Puyraveau, Julien Behr, et al.. (2023). Score to Predict the Occurrence of Pneumothorax After Computed Tomography-guided Percutaneous Transthoracic Lung Biopsy. Journal of Thoracic Imaging. 38(5). 315–324. 1 indexed citations
6.
Eberst, Guillaume, Déwi Vernerey, Caroline Laheurte, et al.. (2022). Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer. BMC Cancer. 22(1). 529–529. 17 indexed citations
7.
Eberst, Guillaume, Lucie Laurent, Aurélia Meurisse, et al.. (2022). Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia. Annals of Intensive Care. 12(1). 23–23. 39 indexed citations
8.
Anota, Amélie, Astrid Pozet, François-Emery Cotté, et al.. (2021). Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review. Quality of Life Research. 31(3). 645–657. 11 indexed citations
9.
Boullerot, Laura, Caroline Laheurte, Amandine Martin, et al.. (2020). Association of reinvigoration of circulating anti-telomerase CD4 Th1 response in cancer patients with anti-PD-1 response.. Journal of Clinical Oncology. 38(15_suppl). 3044–3044. 1 indexed citations
10.
Eberst, Guillaume, Amélie Anota, Arnaud Scherpereel, et al.. (2019). Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. Clinical Cancer Research. 25(19). 5759–5765. 15 indexed citations
11.
Laheurte, Caroline, Magalie Dosset, Déwi Vernerey, et al.. (2019). Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. British Journal of Cancer. 121(5). 405–416. 67 indexed citations
12.
Mouillet, Guillaume, Antoine Thiery-Vuillemin, Hamadi Almotlak, et al.. (2019). Physicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients. Annals of Oncology. 30. v729–v730.
13.
14.
Eberst, Guillaume, et al.. (2018). Complication hémorragique inattendue pour un cancer bronchique sous double immunothérapie. Revue des Maladies Respiratoires. 35(9). 974–977.
15.
Picard, Émilie, Yann Godet, Caroline Laheurte, et al.. (2018). Circulating NKp46+Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer. OncoImmunology. 8(2). e1527498–e1527498. 29 indexed citations
16.
Westeel, Virginie, Guillaume Eberst, Amélie Anota, et al.. (2018). Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.. Journal of Clinical Oncology. 36(15_suppl). 8505–8505. 2 indexed citations
17.
Soumagne, Thibaud, Alicia Guillien, Marc Puyraveau, et al.. (2017). Dans la mucoviscidose, un indice de clairance pulmonaire élevé est associé à des anomalies de fonction pulmonaire à l’exercice chez des adolescents avec spirométrie normale. Revue des Maladies Respiratoires. 34. A32–A32. 1 indexed citations
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Collot Breakdown of academic impact, for papers by Xiaokai Feng Breakdown of academic impact, for papers by Changxing Ou Breakdown of academic impact, for papers by Thomas A Kite Breakdown of academic impact, for papers by Alexandra M. Adams Breakdown of academic impact, for papers by Lan Le Breakdown of academic impact, for papers by Paola Vignali Breakdown of academic impact, for papers by Yoshimasa Otani Breakdown of academic impact, for papers by Donatella Casartelli Breakdown of academic impact, for papers by Anabella Lucca Bianchi
Rankless by CCL
2026